Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mylan unsolicited offer to acquire Perrigo lapses

Executive Summary

Mylan NV made an unsolicited offer to acquire public OTC and generic pharmaceuticals company Perrigo Co. PLC in a cash and stock transaction valued at $28.9bn. Perrigo shareholders would receive $205 in combined cash and Mylan stock representing a 24.2% premium. The Perrigo board is currently evaluating the unsolicited offer. The companies have had ongoing discussions over a potential combination over the past few years. If approved, this would be Mylan's largest M&A to date.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies